Cipher Net Income Per Share from 2010 to 2026
| CPH Stock | CAD 14.81 -0.35 -2.31% |
Net Income Per Share | First Reported 2010-12-31 | Previous Quarter 0.42 | Current Value 0.44 | Quarterly Volatility 0.58442288 |
Review Cipher Pharmaceuticals financial statements over time to add context on performance and capital structure. This context pairs drivers like Depreciation And Amortization of 4.9 M, Interest Expense of 506.9 K or Selling General Administrative of 8.8 M and ratios such as Price To Sales Ratio of 14.31, Dividend Yield of 0.0458 or PTB Ratio of 5.25 with Cipher Pharmaceuticals Valuation and Volatility views.
Cipher | Net Income Per Share |
Evaluating Cipher Pharmaceuticals's Net Income Per Share across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cipher Pharmaceuticals's fundamental strength.
Latest Cipher Pharmaceuticals' Net Income Per Share Growth Pattern
Below is the plot of the Net Income Per Share of Cipher Pharmaceuticals over the last few years. It is Cipher Pharmaceuticals' Net Income Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cipher Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income Per Share | 10 Years Trend |
|
Net Income Per Share |
| Timeline |
Cipher Net Income Per Share Regression Statistics
| Arithmetic Mean | 0.17 | |
| Geometric Mean | 0.26 | |
| Coefficient Of Variation | 350.91 | |
| Mean Deviation | 0.38 | |
| Median | 0.17 | |
| Standard Deviation | 0.58 | |
| Sample Variance | 0.34 | |
| Range | 2.5541 | |
| R-Value | 0.45 | |
| Mean Square Error | 0.29 | |
| R-Squared | 0.20 | |
| Significance | 0.07 | |
| Slope | 0.05 | |
| Total Sum of Squares | 5.46 |
Cipher Net Income Per Share History
Cipher Pharmaceuticals Valuation Metrics
Cipher Pharmaceuticals is a small-cap equity in Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care categories. Cash-flow stability anchors valuation sensitivity. We review the company from a portfolio-construction standpoint emphasizing diversification and stability.
Methodology
Unless otherwise specified, financial data for Cipher Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cipher (CA:CPH) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.
Assumptions
Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Cipher Pharmaceuticals may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Pair Trading with Cipher Pharmaceuticals
Pair trading with Cipher Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Tax-loss harvesting on Cipher Pharmaceuticals requires identifying a similar asset to hold during the mandatory 30-day wash-sale waiting period. Assets with high correlation to Cipher Pharmaceuticals can serve this role while preserving the investor's desired market exposure.
Correlation analysis for Cipher Pharmaceuticals reveals which assets move together and which provide hedging benefits. When two assets have a correlation close to +1, holding both alongside Cipher Pharmaceuticals offers minimal diversification value.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can be used to frame hedging context. The method can be applied across sectors and broader equity sets.More Resources for Cipher Stock Analysis
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help frame valuation context across profits, cash flow, and enterprise value. They help compare Cipher across valuation measures and peers.